{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000003","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.090243+00:00","generated_at":"2026-05-16T10:50:02.257240+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13","bullets":["Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).","FY2025 total U.S. net product sales ~$410M; FILSPARI full-year sales ~$322M.","Cash, equivalents and marketable securities ~$323M at year-end 2025.","FSGS sNDA PDUFA target date Jan 13, 2026; responses to FDA's info requests submitted and under review.","Pegtibatinase Phase 3 HARMONY study to restart in Q1 2026 after manufacturing optimization."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000003","json":"https://secwatch.observer/filing/0001438533-26-000003.json","markdown":"https://secwatch.observer/filing/0001438533-26-000003.md","text":"https://secwatch.observer/filing/0001438533-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/0001438533-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/tvtx-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:50:02.257240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}